

CLAIMS

Listing of Claims:

1. (currently amended) A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation consisting of: an effective amount of mometasone furoate, a dry powder surfactant and HFA 227; wherein the surfactant is present in an amount from about 0.002 to about 0.01% by weight; wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laureate; wherein a percent of fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μ m.
2. (original) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the mometasone furoate is present in an amount of about 50 μ g to about 400 μ g.
3. (original) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 2, wherein the mometasone furoate is present in an amount of about 100 μ g.
4. (original) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 2, wherein the mometasone furoate is present in an amount of about 200 μ g.
5. (original) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 2, wherein the mometasone furoate is present in an amount of about 400 μ g.

6. (canceled) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laureate.

7. (original) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the formulation is free of additional excipients, and wherein the metered dose inhaler emits a dose having uniform drug content upon actuation of the metered dose inhaler.

8. (canceled) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the percent of fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

9. (previously presented) The metered dose inhaler according to claim 1, wherein the percent of fine particles dispensed upon actuation of the metered dose inhaler is about 65% to about 80%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

Claims 10-20 previously canceled without prejudice.

21. (currently amended) A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate, a dry powder surfactant and HFA 227, wherein the formulation is free of a bulking agent lactose; wherein the surfactant is present in an amount from about 0.002 to about 0.01% by weight; wherein the percent of fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about

4.7 μ m; wherein the mometasone furoate is present in an amount of about 50 μ g to about 400 μ g.

22. (canceled) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein the mometasone furoate is present in an amount of about 50 μ g to about 400 μ g.

23. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein the mometasone furoate is present in an amount of about 100 μ g.

24. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein the mometasone furoate is present in an amount of about 200 μ g.

25. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein the mometasone furoate is present in an amount of about 400 μ g.

26. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laureate.

27. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein the formulation is free of additional excipients.

28. (canceled) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 21, wherein a the percent of fine particles

dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

29. (previously presented) The metered dose inhaler according to claim 21, wherein the percent of fine particles dispensed upon actuation of the metered dose inhaler is about 65% to about 80%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

30. (currently amended) A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate, a dry powder surfactant and HFA 227, wherein the formulation is free of additional excipients, wherein the surfactant is present in an amount from about 0.002 to about 0.01% by weight; wherein a percent of fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μ m; wherein the mometasone furoate is present in an amount of about 50 μ g to about 400 μ g.

31. (canceled) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 30, wherein the mometasone furoate is present in an amount of about 50 μ g to about 400 μ g.

32. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 30, wherein the mometasone furoate is present in an amount of about 100 μ g.

33. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 30, wherein the mometasone furoate is present in an amount of about 200 μ g.

34. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 30, wherein the mometasone furoate is present in an amount of about 400 µg.

35. (previously presented) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 30, wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laureate.

36. (canceled) The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 30, wherein the percent of fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7µm.

37. (previously presented) The metered dose inhaler according to claim 30, wherein the percent of fine particles dispensed upon actuation of the metered dose inhaler is about 65% to about 80%, and wherein said fine particles have a particle size of less than about 4.7µm.

38. (Currently amended) A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate, a dry powder surfactant and HFA 227, wherein the formulation is free of lactose; wherein the surfactant is present in an amount from 0.002 to 0.01% by weight; wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laureate; wherein a percent of fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7µm; wherein the mometasone furoate is present in an amount of about 50 µg to about 400 µg.